Can these Trump winners extend their gains?

Should you continue to buy these Trump winners?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Following Donald Trump’s surprise election victory, there are some clear winners and losers in the stock markets. Mining, healthcare, financial and defence stocks rallied strongly last week, while defensive sectors such as utilities and consumer staples lost ground.

However, with Trump widely seen as an erratic and unpredictable character, it’s unclear which sectors, and in particular which stocks, will genuinely benefit in the long run. With this in mind, I’m taking a look at whether Trump winners BAE Systems (LSE: BA) and Shire (LSE: SHP) can extend their earlier gains.

More defence spending?

Defence stocks, such as BAE Systems have been flying high, and on the surface, it makes a lot of sense. Trump has pledged to strengthen the military, with particular emphasis on traditional military firepower – a larger army, more navy ships, more fighter aircraft and better nuclear and missile defence capabilities. Defence analysts reckon that if he follows through on what he’s promised, his defence initiatives would add more than $50bn to the US defence budget annually.

With the Republicans maintaining control of Congress, you’d think that Trump is in a strong position to deliver on more defence spending. However, things are never as simple as they seem. The Republicans have a smaller majority in the House than in 2014, and Senate Democrats could still filibuster everything.

In addition, Trump is relying on unrealistic cost savings and efficiency improvement to deliver what he’s promised and has many competing pledges, ranging from increasing infrastructure spending to cutting taxes and reducing the national debt – all of which will no doubt compete for funding.

BAE, which derives 36% of its revenues from the US, may also be hit by Trump’s protectionist views. He’s pledged to bring back jobs to America, and would likely favour US contractors over foreign ones.

Despite this, shares in BAE are up 10.2% in just a week, and currently trade at 14 times expected earnings this year. This forward price-to-earnings multiple is below its five-year historical average of 18.1, which indicates shares in BAE still seem undervalued despite recent gains. 

Policy uncertainty

Trump’s election win has been good news for healthcare stocks and one of the top performers in the London market has been Shire, a biotechnology company that focuses on rare diseases. Shire gets nearly all of its revenues from the US, so it’s no surprise that the stock is more sensitive to potential US policy shifts than GlaxoSmithKline or AstraZeneca.

While both candidates were critical of high drug prices, Trump has been less vocal on measures to regulate prices and has been more supportive of deregulation. This could cut development costs and speed up the approval process – and boost profits for the sector. Nevertheless, he hasn’t given any specifics on his health plan yet, and the potential long-term benefit for the sector remains to be seen.

Shares in Shire already gained 9.9% this week, and currently trade at a forward P/E of 11.4. Although this is significantly below its five-year historical average of 20.8, the firm’s recent disappointing haemophilia drug sales figures point towards slowing earnings growth in the near term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young lady working from home office during coronavirus pandemic.
Top Stocks

5 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Young Asian man drinking coffee at home and looking at his phone
Dividend Shares

These 3 FTSE 250 stocks offer me the highest dividend yields, but should I buy?

Jon Smith considers FTSE 250 shares with a very high yield, but questions whether the income is going to be…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Is FTSE 100 takeover target DS Smith a great buy?

A mega-merger between FTSE 100 giants DS Smith and Mondi has the City abuzz. But is there any value in…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

The WPP share price dips as profits fall. Here’s why it could be a top dividend buy

I'm starting to think the WPP share price undervalues the stock, especially if the long-term dividend outlook comes good.

Read more »

Black father and two young daughters dancing at home
Investing Articles

A £3K investment buys me 632 shares in 2 stocks for a second income!

This Fool explains how a second income is possible through dividend-paying stocks and details two picks that could help her.

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Here’s what these results tell me about the Lloyds share price

A policy of progressive shareholder returns, including big dividend yields, makes the Lloyds share price look super cheap to me.

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

Passive income from 9.2% yield stock could cut pressure as costs spike

Passive income is one way to reduce the pressure on families, especially as a new study finds a third of…

Read more »

Rainbow foil balloon of the number two on pink background
Investing Articles

2 FTSE 100 dividend shares I’d buy to build £15k passive income

Building long-term passive income is an important part of my investment strategy. Here’s a couple of Footsie shares that I…

Read more »